title: Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept.
authors.forename: R
authors.initials: R
authors.lastname: Priori
authors.forename: C
authors.initials: C
authors.lastname: Alessandri
authors.forename: L
authors.initials: L
authors.lastname: Magrini
authors.forename: E A M
authors.initials: EA
authors.lastname: Cassarà
authors.forename: F
authors.initials: F
authors.lastname: Ceccarelli
authors.forename: M
authors.initials: M
authors.lastname: Modesti
authors.forename: C
authors.initials: C
authors.lastname: Croia
authors.forename: M
authors.initials: M
authors.lastname: Bombardieri
authors.forename: G
authors.initials: G
authors.lastname: Valesini
mesh_terms: D000068879:Adalimumab; D000974:Antibodies, Antinuclear / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000378:metabolism*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D009707:Nucleosomes / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
chemical_list: D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D009707:Nucleosomes; D018124:Receptors, Tumor Necrosis Factor; D002097:C-Reactive Protein; D000068879:Adalimumab; D000068800:Etanercept